Home > Insider Trading > Filing (0001179110-17-010703)

Filing Details

Accession Number:: 0001179110-17-010703
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-07-26 16:31:21
Reporting Period:: 2017-07-25

Filing Date:: 2017-07-26
Accepted Time:: 2017-07-26 16:31:21
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1479419	Kala Pharmaceuticals Inc.	KALA	Pharmaceutical Preparations (2834)	270604595

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1619841	M. Rajeev Shah	C/O Ra Capital Management, Llc 20 Park Plaza, Suite 1200 Boston MA 02116		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-07-25	1,579,903	$0.00	1,579,903	No	4	C	Indirect	See footnote.
Common Stock	Acquisiton	2017-07-25	533,333	$15.00	2,113,236	No	4	P	Indirect	See footnote.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote.
No	4	P	Indirect	See footnote.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2017-07-25	3,819,444	$0.00	733,337	$0.00
Common Stock	Series C Preferred Stock	Disposition	2017-07-25	4,409,170	$0.00	846,566	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The Series B Preferred Stock and Series C Preferred Stock converted into Common Stock on a 5.2083-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Includes (a) 1,300,057 shares of Common Stock that are held by RA Capital Healthcare Fund, L.P. and (b) 279,846 shares of Common Stock that are held in an account owned by a separately managed account (the "Account").
Includes (a) 427,043 shares of Common Stock held by RA Capital Healthcare Fund, L.P. and (b) 106,290 held in the Account, in each case acquired in the Issuer's initial public offering.
Includes (a) 3,143,402 shares of Series B Convertible Preferred Stock that were held by RA Capital Healthcare Fund, L.P. and (b) 676,042 shares of Series B Convertible Preferred Stock that were held in the Account.
Includes (a) 3,627,688 shares of Series C Convertible Preferred Stock that were held by RA Capital Healthcare Fund, L.P. and (b) 781,482 shares of Series C Convertible Preferred Stock that were held in the Account.
RA Capital Management, LLC (the "Adviser") is the general partner of RA Capital Healthcare Fund, L.P. and the investment adviser of the Account. Peter Kolchinsky is the sole manager of the Adviser, and Mr. Shah is a member of the Adviser. Mr. Shah has no pecuniary interest in the reported securities held in the Account and therefore disclaims beneficial ownership of those securities. Mr. Shah disclaims beneficial ownership of the reported securities held by the RA Capital Healthcare Fund, L.P. except to the extent of his pecuniary interest therein.